Butterfly Network Receives $5 Million Grant to Advance Maternal and Fetal Health

Butterfly will provide 1,000 healthcare workers in sub-Saharan Africa with the technology and training needed to enable better clinical decision-making through point-of-care ultrasound

GUILFORD, Connecticut and NEW YORK, March 09, 2022–(BUSINESS WIRE)–Butterfly Network, Inc. (NYSE: BFLY), a digital health company transforming care through wearable full-body ultrasound, today announced that it has received a grant from a $5 million from the Bill & Melinda Gates Foundation to improve maternal and fetal health. With this grant, Butterfly will provide 1,000 healthcare workers in sub-Saharan Africa with Butterfly iQ+, the world’s only wearable full-body ultrasound probe.

Pregnancy complications are among the major contributors to morbidity and mortality in resource-limited health care settings. Butterfly will bring 1,000 Butterfly iQ+ probes to sub-Saharan Africa to improve community access to medical imaging. As part of this initiative, 500 catheters will be donated to mid-level practitioners in Kenya and 500 will be distributed to healthcare workers in South Africa; both distributions will focus on improving maternal and fetal health.

“Many places around the world, especially low- and middle-income countries, are diagnostic deserts, leaving practitioners with virtually no imaging modalities to aid in the diagnosis and subsequent treatment of patients,” said Dr. Todd. Fruchterman, President and CEO of Butterfly Network. “At Butterfly, we have long imagined and innovated for the next generation of points of service. With this grant, we are taking another important step towards improving global access to medical imaging and will also demonstrate how mid-level practitioners can significantly improve care for pregnant women and their unborn children. »

“For years, the Gates Foundation has supported Butterfly’s efforts to improve healthcare where it’s needed most,” said Darius Shahida, director of strategy and business development at Butterfly Network. “This new grant represents an important step towards that goal in its ability to signal the transformational impact of Butterfly’s technology in some of the most remote settings.

Butterfly Network will document best practices for the use of point-of-care ultrasound that can be leveraged to optimize the qualitative and quantitative clinical and economic impact of Butterfly iQ+ deployments in other care settings. Additionally, a portion of this grant will also be used to accelerate the launch of new maternal and fetal health features available in the Butterfly iQ+ mobile app.

To learn more about the impact of Butterfly technology and to view a demonstration of Butterfly iQ+, please visit: https://www.butterflynetwork.com.

About the Butterfly Network
Founded by Dr. Jonathan Rothberg in 2011 and listed on the New York Stock Exchange as part of a business combination with Longview Acquisition Corp., Butterfly has created the world’s first portable, single-probe body ultrasound system using semitrailer technology. -drivers, the Butterfly iQ+. Butterfly’s mission is to democratize medical imaging and contribute to the aspiration for global health equity, by making high quality ultrasound affordable, easy to use, globally accessible and intelligently connected. , including for the 4.7 billion people worldwide who do not have access to ultrasound. . With its proprietary Ultrasound-on-Chip™ technology, Butterfly is leading the way in early detection and remote management of health conditions worldwide. Butterfly iQ+ can be purchased online today by healthcare professionals in the United States, Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, New Zealand, Norway, Poland, Portugal, Spain, Sweden, Switzerland and the United Kingdom.

Butterfly iQ+ is a prescription device intended for qualified healthcare professionals only.

Forward-looking statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. The Company’s actual results may differ from its expectations, estimates and projections and, therefore, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect”, “estimate”, “project”, “budget”, “expect”, “anticipate”, “intend”, “plan”, “may”, “will” , “could”, “should”, “believes”, “predicts”, “potential”, “continues” and similar expressions (or negative versions of such words or expressions) are intended to identify such forward-looking statements. Such statements forward-looking statements include, but are not limited to, the Company’s expectations regarding financial results, future performance, development of products and services, and the size and potential growth of current or future markets for its products and services. forward-looking statements involve significant risks and uncertainties that could cause actual results to differ materially from those discussed in the forward-looking statements. Many of these factors are beyond the control of the Company and are difficult to predict. Factors that could between Other such differences include, but are not limited to: the impact of COVID-19 on the Company’s business, including issues with Omicron or other variants; the ability to recognize the expected benefits of the business combination; the Company’s ability to grow and manage growth profitably; the success, cost and timing of the Company’s product and service development activities; the attributes and potential benefits of the Company’s products and services; the degree to which our products and services are accepted by healthcare practitioners and patients for their approved uses; the Company’s ability to obtain and maintain regulatory approval for its products, and any related restrictions and limitations of any approved products; the Company’s ability to identify, license or acquire additional technology; the Company’s ability to maintain its existing licensing, manufacturing, supply and distribution agreements; manufacture and supply of the Company’s products; the Company’s ability to compete with other companies that currently market or are engaged in developing products and services that the Company currently markets or develops; changes in applicable laws or regulations; the size and growth potential of markets for the Company’s products and services, and its ability to serve those markets, either alone or in partnership with others; pricing of the Company’s products and services and reimbursement for medical procedures performed using its products and services; the Company’s estimates of expenses, revenues, capital requirements and additional financing requirements; the financial performance of the Company; the Company’s ability to raise funds in the future; and other risks and uncertainties discussed from time to time in the company’s most recent Annual Report on Form 10-K or in subsequent filings with the Securities and Exchange Commission. The Company cautions that the above list of factors is not exclusive. The Company cautions you not to place undue reliance on forward-looking statements, which speak only as of the date of this press release. The Company neither undertakes nor accepts any obligation or undertakes to issue any updates or revisions to any forward-looking statements to reflect any change in the Company’s expectations or any change in events, conditions or circumstances on which such statement is based.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220309005216/en/


butterfly network

spring holly
[email protected]

Agnes Lee
[email protected]

Comments are closed.